| Drug General Information |
| Drug ID |
D0EG1I
|
| Former ID |
DNAP001690
|
| Drug Name |
Tofacitinib
|
| Synonyms |
Xeljanz (TN)
|
| Drug Type |
Small molecular drug
|
| Indication |
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06]
|
Approved |
[1],
[2],
[3]
|
|---|
| Company |
Pfizer
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H20N6O
|
| InChI |
InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1
|
| InChIKey |
UJLAWZDWDVHWOW-YPMHNXCESA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14898931, 16573063, 24203044, 50100095, 56468341, 56479518, 80408829, 93578178, 93578180, 99005545, 99436938, 99444654, 103506979, 104076339, 109693014, 118049771, 124757868, 124939204, 124939205, 125164719, 126617354, 126636329, 131541360, 134344290, 135253188, 135626691, 135697694, 135723912, 136367982, 137055230, 142909486, 143498234, 144115851, 152159600, 152239919, 152258788, 152344045, 160646103, 160647639, 160819105, 160969237, 162011739, 162133672, 162193956, 162766622, 164043529, 164194011, 164783370, 170482324, 170482440
|
| ChEBI ID |
ChEBI:71200
|
| SuperDrug ATC ID |
L04AA29
|
| Target and Pathway |
| Target(s) |
Tyrosine-protein kinase JAK3 |
Target Info |
Modulator |
[3]
|
|---|
|
KEGG Pathway
|
Chemokine signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Jak-STAT signaling pathway
|
|
Measles
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesis
|
|
Primary immunodeficiency
|
|
PANTHER Pathway
|
Interleukin signaling pathway
|
|
JAK/STAT signaling pathway
|
|
PDGF signaling pathway
|
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
|
CD40/CD40L signaling
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
IL2-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
IL2 signaling events mediated by STAT5
|
|
Reactome
|
GPVI-mediated activation cascade
|
|
Interleukin-7 signaling
|
|
G beta:gamma signalling through PI3Kgamma
|
|
Interleukin-2 signaling
|
|
RAF/MAP kinase cascade
|
|
Interleukin receptor SHC signaling
|
|
WikiPathways
|
IL-2 Signaling Pathway
|
|
IL-4 Signaling Pathway
|
|
Interleukin-2 signaling
|
|
Interleukin-7 signaling
|
|
Oncostatin M Signaling Pathway
|
|
IL-9 Signaling Pathway
|
|
IL-7 Signaling Pathway
|
|
Interleukin-3, 5 and GM-CSF signaling
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02157012) Evaluation of the Condition of Rheumatoid Arthritis After Treatment. U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5677). |
|---|
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
|---|
